Drug Search Results

Resiniferatoxin

Alternative Names: resiniferatoxin, lopain, mtx-071
Latest Update: 2024-12-19
Latest Update Note: Clinical Trial Update

Product Description

Sorrento is developing Resiniferatoxin as a treatment for pain due to Knee Osteoarthritis (OA). (Sourced from: https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-begins-enrollment-phase-2-trial-resiniferatoxin-rtx)

Mechanisms of Action: TRPV1 Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Injection

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Sorrento
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Resiniferatoxin

Countries in Clinic: United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 2: Chronic Pain|Pain, Intractable

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
RTX-CAP-201	P2	Suspended	Pain, Intractable	2027-06-01	32%
2018-000818-37	P2	Completed	Chronic Pain	2023-01-26

Recent News Events

Date	Type	Title
10/22/2024	News Article	First participants enrolled in first-in-human Phase I clinical trial with nociceptin (NOP) receptor agonist
05/01/2024	PubMed	TRPV1: Receptor structure, activation, modulation and role in neuro-immune interactions and pain.
04/17/2024	PubMed	Capsaicin modulates Akkermansia muciniphila abundance by enhancing MUCIN2 levels in mice fed with high-fat diets.
04/01/2024	PubMed	CGRP Released by Corneal Sensory Nerve Maintains Tear Secretion of the Lacrimal Gland.
09/22/2023	News Article	Sorrento Therapeutics, Inc. Announces the Consummation of the Previously Announced Sale of Substantially All of the Common Shares, Preferred Shares and Warrants that Sorrento Held in Scilex Holding Company
09/20/2023	News Article	2023 Studio Headphones and Headsets Market Future Growth and Demand 2030
09/12/2023	News Article	Sorrento Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso (Olgotrelvir), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions